We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Aevi Genomic Medicine, Inc. (“Aevi” or the “Company”) (NASDAQ: GNMX) to Cerecor Inc. (“Cerecor”) (NASDAQ: CERC). Under the terms of the agreement, Aevi stockholders are anticipated to receive up to $0.134 per share in the form of Cerecor stock, after adjusting for Aevi’s net assets at closing.
The Aevi merger investigation concerns whether the Board of Aevi breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction and whether Cerecor is underpaying for Aevi shares, thus unlawfully harming Aevi shareholders.
To receive more information, please fill out the form.